Header image for  Pareto Securities’ 11th Annual Healthcare Conference
Profile image for Immunovia

Immunovia Exhibitor

Type of industry

Biotech

Presentation
Immunovia AB is a diagnostic company that has developed and is commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q4 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.

Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and Lund, Sweden will provide laboratory testing services in two accredited reference laboratories.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

Presentations

Immunovia

Wednesday September 2, 2020 16:00 - 16:30 CEST Room 2

Representatives

Mats Grahn SpeakerExhibitor

CEO
Immunovia

Gabriela Urquilla Exhibitor

Investor Relations
Immunovia

Julie Silber Exhibitor

Immunovia